Share Price and Basic Stock Data
Last Updated: January 10, 2026, 7:29 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Themis Medicare Ltd, operating in the pharmaceuticals sector, reported a current market capitalization of ₹981 Cr with a share price of ₹106. The company has shown a fluctuating revenue trend, with total sales for the trailing twelve months (TTM) standing at ₹341 Cr. Sales have seen a peak in the fiscal year ending March 2022 at ₹395 Cr, followed by a decline to ₹354 Cr in March 2023. However, the fiscal year 2024 is projected to improve slightly to ₹382 Cr, suggesting a potential recovery. Quarterly sales figures have also varied, with ₹104.78 Cr noted in September 2023, up from ₹91 Cr in September 2022, indicating a positive growth trajectory. Nonetheless, the company has faced challenges, as evidenced by the declining sales in certain quarters, notably the drop to ₹80.10 Cr in March 2023. The volatility in sales indicates both opportunities for growth and hurdles that need addressing for sustained performance.
Profitability and Efficiency Metrics
Themis Medicare reported a net profit of -₹27 Cr for the fiscal year ending March 2025, highlighting significant profitability challenges. The operating profit margin (OPM) has been negative at -3.97% for the same period, down from a high of 24% in March 2022, indicating declining operational efficiency. Quarterly results reflect this trend, with the operating profit plunging to -₹7.70 Cr in March 2025. Return on equity (ROE) has been reported at 7.65%, which is relatively low compared to industry standards, suggesting that the company is not utilizing its equity effectively to generate profits. The interest coverage ratio (ICR) stood at a healthy 5.35x, indicating that Themis can comfortably meet its interest obligations. However, the cash conversion cycle (CCC) of 250 days is notably high, reflecting inefficiencies in inventory management and receivables collection that could impact cash flow.
Balance Sheet Strength and Financial Ratios
The balance sheet of Themis Medicare shows total reserves of ₹371 Cr against borrowings of ₹96 Cr, indicating a solid equity base relative to its liabilities. The debt-to-equity ratio stands at 0.20, which is favorable compared to typical sector norms, suggesting a conservative leverage position. The company’s book value per share is reported at ₹43.74, and the price-to-book value (P/BV) ratio is 3.35x, indicating that the stock is trading at a premium. Key financial ratios reflect a mixed performance; for instance, return on capital employed (ROCE) is reported at 10.4%, which is reasonable but lower than historical highs. The current ratio of 1.95 signifies adequate short-term liquidity, but the declining trend in net profit margins—from 15.59% in March 2022 to 5.89% in March 2025—highlights profitability concerns that need addressing. Overall, while the balance sheet suggests stability, profitability metrics indicate significant areas for improvement.
Shareholding Pattern and Investor Confidence
Themis Medicare’s shareholding structure is predominantly controlled by promoters, who hold 67.15% of the equity, reflecting strong management control. The presence of foreign institutional investors (FIIs) is negligible at 0.06%, while domestic institutional investors (DIIs) account for only 0.01%. This limited institutional interest may suggest a lack of confidence from larger investors, which could impact stock liquidity and market perception. The number of shareholders has increased significantly from 6,362 in December 2022 to 22,490 by September 2025, indicating growing retail interest. However, the low participation from institutional investors might raise questions about the company’s attractiveness in the broader market. The stability in promoter holdings alongside increasing public participation could be a positive sign, but the overall lack of institutional backing poses a risk to stock performance and potential volatility.
Outlook, Risks, and Final Insight
Looking ahead, Themis Medicare’s prospects will largely depend on its ability to stabilize profitability and enhance operational efficiency. The recent uptick in quarterly sales figures is promising, but the ongoing negative net profit and operating margins present significant risks. Additionally, the high cash conversion cycle could hamper liquidity, especially in a competitive pharmaceuticals market. Strengths include a solid balance sheet with low leverage and a strong promoter holding, which can provide stability in times of market volatility. However, the company must address its profitability issues and inefficient operational metrics to attract institutional investors. If Themis can successfully implement strategies to improve margins and operational efficiency, it may enhance investor confidence and market performance, potentially leading to a more favorable outlook. Conversely, failure to address these issues may result in continued financial strain and market skepticism.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 208/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,259 Cr. | 391 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.9 Cr. | 39.5 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,294.49 Cr | 1,133.13 | 52.77 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91.00 | 88.78 | 80.10 | 96.65 | 104.78 | 82.51 | 97.82 | 122.99 | 117.01 | 93.81 | 71.70 | 97.58 | 77.99 |
| Expenses | 69.66 | 73.51 | 69.62 | 74.91 | 92.37 | 74.46 | 88.53 | 93.81 | 99.88 | 87.84 | 79.40 | 107.80 | 81.09 |
| Operating Profit | 21.34 | 15.27 | 10.48 | 21.74 | 12.41 | 8.05 | 9.29 | 29.18 | 17.13 | 5.97 | -7.70 | -10.22 | -3.10 |
| OPM % | 23.45% | 17.20% | 13.08% | 22.49% | 11.84% | 9.76% | 9.50% | 23.73% | 14.64% | 6.36% | -10.74% | -10.47% | -3.97% |
| Other Income | 6.22 | 7.13 | 5.32 | 6.29 | 6.66 | 5.94 | 4.67 | 6.93 | 5.56 | 1.02 | 1.55 | 1.18 | 4.98 |
| Interest | 2.37 | 2.23 | 2.71 | 2.49 | 2.04 | 2.68 | 2.16 | 2.36 | 2.44 | 2.79 | 2.45 | 2.47 | 2.76 |
| Depreciation | 2.56 | 2.67 | 2.80 | 3.03 | 3.07 | 3.10 | 3.06 | 2.41 | 2.45 | 2.54 | 2.53 | 2.55 | 2.57 |
| Profit before tax | 22.63 | 17.50 | 10.29 | 22.51 | 13.96 | 8.21 | 8.74 | 31.34 | 17.80 | 1.66 | -11.13 | -14.06 | -3.45 |
| Tax % | 21.43% | 23.94% | 18.37% | 19.19% | 18.91% | 10.35% | 24.14% | 21.25% | 19.66% | 68.67% | -13.12% | 1.14% | 4.64% |
| Net Profit | 17.78 | 13.31 | 8.41 | 18.19 | 11.32 | 7.37 | 6.64 | 24.68 | 14.29 | 0.52 | -9.66 | -14.22 | -3.62 |
| EPS in Rs | 1.93 | 1.45 | 0.91 | 1.98 | 1.23 | 0.80 | 0.72 | 2.68 | 1.55 | 0.06 | -1.05 | -1.54 | -0.39 |
Last Updated: December 28, 2025, 8:05 pm
Below is a detailed analysis of the quarterly data for Themis Medicare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 77.99 Cr.. The value appears to be declining and may need further review. It has decreased from 97.58 Cr. (Jun 2025) to 77.99 Cr., marking a decrease of 19.59 Cr..
- For Expenses, as of Sep 2025, the value is 81.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 107.80 Cr. (Jun 2025) to 81.09 Cr., marking a decrease of 26.71 Cr..
- For Operating Profit, as of Sep 2025, the value is -3.10 Cr.. The value appears strong and on an upward trend. It has increased from -10.22 Cr. (Jun 2025) to -3.10 Cr., marking an increase of 7.12 Cr..
- For OPM %, as of Sep 2025, the value is -3.97%. The value appears strong and on an upward trend. It has increased from -10.47% (Jun 2025) to -3.97%, marking an increase of 6.50%.
- For Other Income, as of Sep 2025, the value is 4.98 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Jun 2025) to 4.98 Cr., marking an increase of 3.80 Cr..
- For Interest, as of Sep 2025, the value is 2.76 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.47 Cr. (Jun 2025) to 2.76 Cr., marking an increase of 0.29 Cr..
- For Depreciation, as of Sep 2025, the value is 2.57 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.55 Cr. (Jun 2025) to 2.57 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is -3.45 Cr.. The value appears strong and on an upward trend. It has increased from -14.06 Cr. (Jun 2025) to -3.45 Cr., marking an increase of 10.61 Cr..
- For Tax %, as of Sep 2025, the value is 4.64%. The value appears to be increasing, which may not be favorable. It has increased from 1.14% (Jun 2025) to 4.64%, marking an increase of 3.50%.
- For Net Profit, as of Sep 2025, the value is -3.62 Cr.. The value appears strong and on an upward trend. It has increased from -14.22 Cr. (Jun 2025) to -3.62 Cr., marking an increase of 10.60 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.39. The value appears strong and on an upward trend. It has increased from -1.54 (Jun 2025) to -0.39, marking an increase of 1.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:30 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 202 | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 406 | 341 |
| Expenses | 171 | 184 | 194 | 184 | 184 | 181 | 166 | 181 | 299 | 287 | 330 | 356 | 356 |
| Operating Profit | 24 | 18 | 38 | 33 | 25 | 2 | 36 | 49 | 96 | 67 | 52 | 49 | -15 |
| OPM % | 12% | 9% | 16% | 15% | 12% | 1% | 18% | 21% | 24% | 19% | 13% | 12% | -4% |
| Other Income | 5 | 13 | 3 | 4 | 6 | 5 | 12 | 13 | 18 | 25 | 24 | 11 | 9 |
| Interest | 16 | 15 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 | 10 | 10 |
| Depreciation | 9 | 11 | 12 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 | 10 | 10 |
| Profit before tax | 4 | 5 | 17 | 18 | 11 | -13 | 27 | 41 | 95 | 73 | 53 | 40 | -27 |
| Tax % | 32% | -20% | 11% | 9% | 1% | -15% | 8% | 14% | 23% | 22% | 19% | 25% | |
| Net Profit | 3 | 6 | 16 | 16 | 11 | -11 | 25 | 36 | 73 | 57 | 44 | 30 | -27 |
| EPS in Rs | 0.32 | 0.73 | 1.91 | 1.77 | 1.23 | -1.17 | 2.70 | 3.88 | 7.92 | 6.18 | 4.73 | 3.24 | -2.92 |
| Dividend Payout % | 28% | 25% | 9% | 0% | 0% | 0% | 6% | 11% | 6% | 8% | 11% | 15% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 166.67% | 0.00% | -31.25% | -200.00% | 327.27% | 44.00% | 102.78% | -21.92% | -22.81% | -31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | 66.67% | -166.67% | -31.25% | -168.75% | 527.27% | -283.27% | 58.78% | -124.70% | -0.89% | -9.01% |
Themis Medicare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 1% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 4% |
| 3 Years: | -25% |
| TTM: | -118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 24% |
| 3 Years: | 8% |
| 1 Year: | -59% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: December 4, 2025, 2:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 48 | 51 | 66 | 143 | 160 | 149 | 174 | 209 | 278 | 330 | 368 | 393 | 371 |
| Borrowings | 148 | 140 | 128 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 96 | 83 | 96 |
| Other Liabilities | 79 | 77 | 73 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 93 | 102 | 107 |
| Total Liabilities | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 582 |
| Fixed Assets | 121 | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 172 | 169 |
| CWIP | 12 | 4 | 6 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 | 3 | 3 |
| Investments | 4 | 5 | 6 | 23 | 24 | 27 | 35 | 45 | 56 | 70 | 89 | 95 | 96 |
| Other Assets | 147 | 146 | 146 | 133 | 153 | 162 | 191 | 191 | 225 | 279 | 307 | 318 | 314 |
| Total Assets | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 582 |
Below is a detailed analysis of the balance sheet data for Themis Medicare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Reserves, as of Sep 2025, the value is 371.00 Cr.. The value appears to be declining and may need further review. It has decreased from 393.00 Cr. (Mar 2025) to 371.00 Cr., marking a decrease of 22.00 Cr..
- For Borrowings, as of Sep 2025, the value is 96.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 83.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 13.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 107.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 102.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 582.00 Cr.. The value appears to be improving (decreasing). It has decreased from 588.00 Cr. (Mar 2025) to 582.00 Cr., marking a decrease of 6.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 169.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 169.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Investments, as of Sep 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 318.00 Cr. (Mar 2025) to 314.00 Cr., marking a decrease of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 582.00 Cr.. The value appears to be declining and may need further review. It has decreased from 588.00 Cr. (Mar 2025) to 582.00 Cr., marking a decrease of 6.00 Cr..
Notably, the Reserves (371.00 Cr.) exceed the Borrowings (96.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -124.00 | -122.00 | -90.00 | -49.00 | -55.00 | -80.00 | -64.00 | -38.00 | 16.00 | -25.00 | -44.00 | -34.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 82 | 75 | 81 | 120 | 145 | 186 | 123 | 93 | 149 | 170 | 159 |
| Inventory Days | 280 | 246 | 243 | 250 | 253 | 287 | 315 | 272 | 150 | 213 | 188 | 233 |
| Days Payable | 240 | 237 | 145 | 163 | 156 | 187 | 171 | 143 | 79 | 123 | 126 | 142 |
| Cash Conversion Cycle | 114 | 91 | 172 | 168 | 216 | 244 | 330 | 251 | 164 | 239 | 232 | 250 |
| Working Capital Days | -17 | -20 | -17 | -16 | 19 | -1 | 37 | 51 | 72 | 110 | 116 | 121 |
| ROCE % | 10% | 9% | 15% | 13% | 10% | -1% | 15% | 18% | 30% | 20% | 14% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 322 | 0.08 | 0.01 | 322 | 2025-04-22 17:25:18 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.24 | 4.73 | 61.83 | 79.22 | 38.86 |
| Diluted EPS (Rs.) | 3.24 | 4.72 | 61.73 | 79.07 | 38.84 |
| Cash EPS (Rs.) | 3.68 | 4.02 | 58.44 | 77.19 | 37.85 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 43.74 | 41.03 | 368.85 | 312.48 | 237.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 43.74 | 41.03 | 368.85 | 312.48 | 237.80 |
| Revenue From Operations / Share (Rs.) | 44.06 | 41.48 | 385.02 | 428.91 | 251.04 |
| PBDIT / Share (Rs.) | 5.84 | 6.11 | 85.80 | 111.06 | 57.81 |
| PBIT / Share (Rs.) | 4.76 | 4.78 | 74.39 | 100.75 | 48.50 |
| PBT / Share (Rs.) | 3.67 | 3.76 | 64.00 | 91.22 | 34.67 |
| Net Profit / Share (Rs.) | 2.60 | 2.69 | 47.03 | 66.89 | 28.54 |
| NP After MI And SOA / Share (Rs.) | 3.24 | 4.73 | 61.83 | 79.22 | 38.86 |
| PBDIT Margin (%) | 13.24 | 14.73 | 22.28 | 25.89 | 23.02 |
| PBIT Margin (%) | 10.79 | 11.52 | 19.32 | 23.49 | 19.32 |
| PBT Margin (%) | 8.32 | 9.07 | 16.62 | 21.26 | 13.81 |
| Net Profit Margin (%) | 5.89 | 6.47 | 12.21 | 15.59 | 11.37 |
| NP After MI And SOA Margin (%) | 7.35 | 11.40 | 16.05 | 18.46 | 15.47 |
| Return on Networth / Equity (%) | 7.41 | 11.52 | 16.76 | 25.35 | 16.33 |
| Return on Capital Employeed (%) | 10.13 | 10.68 | 18.26 | 29.12 | 18.35 |
| Return On Assets (%) | 5.07 | 7.68 | 11.07 | 17.03 | 9.61 |
| Long Term Debt / Equity (X) | 0.04 | 0.07 | 0.08 | 0.08 | 0.10 |
| Total Debt / Equity (X) | 0.20 | 0.25 | 0.27 | 0.27 | 0.36 |
| Asset Turnover Ratio (%) | 0.70 | 0.70 | 0.75 | 1.05 | 0.67 |
| Current Ratio (X) | 1.95 | 1.90 | 1.90 | 1.96 | 1.45 |
| Quick Ratio (X) | 1.41 | 1.44 | 1.41 | 1.40 | 0.98 |
| Inventory Turnover Ratio (X) | 5.24 | 1.21 | 1.48 | 1.90 | 1.20 |
| Dividend Payout Ratio (NP) (%) | 15.42 | 10.57 | 8.08 | 5.42 | 4.50 |
| Dividend Payout Ratio (CP) (%) | 11.57 | 8.25 | 6.82 | 4.80 | 3.63 |
| Earning Retention Ratio (%) | 84.58 | 89.43 | 91.92 | 94.58 | 95.50 |
| Cash Earning Retention Ratio (%) | 88.43 | 91.75 | 93.18 | 95.20 | 96.37 |
| Interest Coverage Ratio (X) | 5.35 | 6.00 | 8.26 | 11.64 | 4.18 |
| Interest Coverage Ratio (Post Tax) (X) | 3.38 | 3.64 | 5.53 | 8.01 | 3.06 |
| Enterprise Value (Cr.) | 1419.92 | 2092.17 | 1146.53 | 910.58 | 312.04 |
| EV / Net Operating Revenue (X) | 3.50 | 5.48 | 3.24 | 2.31 | 1.35 |
| EV / EBITDA (X) | 26.43 | 37.19 | 14.52 | 8.91 | 5.87 |
| MarketCap / Net Operating Revenue (X) | 3.33 | 5.28 | 3.03 | 2.18 | 1.12 |
| Retention Ratios (%) | 84.57 | 89.42 | 91.91 | 94.57 | 95.49 |
| Price / BV (X) | 3.35 | 5.34 | 3.16 | 2.99 | 1.18 |
| Price / Net Operating Revenue (X) | 3.33 | 5.28 | 3.03 | 2.18 | 1.12 |
| EarningsYield | 0.02 | 0.02 | 0.05 | 0.08 | 0.13 |
After reviewing the key financial ratios for Themis Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.72 (Mar 24) to 3.24, marking a decrease of 1.48.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.68. This value is within the healthy range. It has decreased from 4.02 (Mar 24) to 3.68, marking a decrease of 0.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 44.06. It has increased from 41.48 (Mar 24) to 44.06, marking an increase of 2.58.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.84. This value is within the healthy range. It has decreased from 6.11 (Mar 24) to 5.84, marking a decrease of 0.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.76. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.76, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.67. This value is within the healthy range. It has decreased from 3.76 (Mar 24) to 3.67, marking a decrease of 0.09.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 2.69 (Mar 24) to 2.60, marking a decrease of 0.09.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
- For PBDIT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has decreased from 14.73 (Mar 24) to 13.24, marking a decrease of 1.49.
- For PBIT Margin (%), as of Mar 25, the value is 10.79. This value is within the healthy range. It has decreased from 11.52 (Mar 24) to 10.79, marking a decrease of 0.73.
- For PBT Margin (%), as of Mar 25, the value is 8.32. This value is below the healthy minimum of 10. It has decreased from 9.07 (Mar 24) to 8.32, marking a decrease of 0.75.
- For Net Profit Margin (%), as of Mar 25, the value is 5.89. This value is within the healthy range. It has decreased from 6.47 (Mar 24) to 5.89, marking a decrease of 0.58.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.35. This value is below the healthy minimum of 8. It has decreased from 11.40 (Mar 24) to 7.35, marking a decrease of 4.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.41. This value is below the healthy minimum of 15. It has decreased from 11.52 (Mar 24) to 7.41, marking a decrease of 4.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has decreased from 10.68 (Mar 24) to 10.13, marking a decrease of 0.55.
- For Return On Assets (%), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.07, marking a decrease of 2.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. There is no change compared to the previous period (Mar 24) which recorded 0.70.
- For Current Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 1.95, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.41, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.21 (Mar 24) to 5.24, marking an increase of 4.03.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.42. This value is below the healthy minimum of 20. It has increased from 10.57 (Mar 24) to 15.42, marking an increase of 4.85.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.57. This value is below the healthy minimum of 20. It has increased from 8.25 (Mar 24) to 11.57, marking an increase of 3.32.
- For Earning Retention Ratio (%), as of Mar 25, the value is 84.58. This value exceeds the healthy maximum of 70. It has decreased from 89.43 (Mar 24) to 84.58, marking a decrease of 4.85.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.43. This value exceeds the healthy maximum of 70. It has decreased from 91.75 (Mar 24) to 88.43, marking a decrease of 3.32.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.35. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 5.35, marking a decrease of 0.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.38. This value is within the healthy range. It has decreased from 3.64 (Mar 24) to 3.38, marking a decrease of 0.26.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,419.92. It has decreased from 2,092.17 (Mar 24) to 1,419.92, marking a decrease of 672.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 3.50, marking a decrease of 1.98.
- For EV / EBITDA (X), as of Mar 25, the value is 26.43. This value exceeds the healthy maximum of 15. It has decreased from 37.19 (Mar 24) to 26.43, marking a decrease of 10.76.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
- For Retention Ratios (%), as of Mar 25, the value is 84.57. This value exceeds the healthy maximum of 70. It has decreased from 89.42 (Mar 24) to 84.57, marking a decrease of 4.85.
- For Price / BV (X), as of Mar 25, the value is 3.35. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 3.35, marking a decrease of 1.99.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Themis Medicare Ltd:
- Net Profit Margin: 5.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.2
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No.69-A, GIDC Industrial Estate, Valsad District Gujarat 396195 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Dinesh S Patel | Chairman & Executive Director |
| Dr. Sachin D Patel | Managing Director & CEO |
| Mr. Rajneesh K Anand | Non Executive Director |
| Dr. Adam Demeter | Non Executive Director |
| Ms. Manjul Sandhu | Independent Director |
| Mr. Bhaskar V Iyer | Independent Director |
| Mr. Nikunt K Raval | Independent Director |
| Ms. Neha Thakore | Independent Director |
| Mr. Shishir V Dalal | Independent Director |
| Mrs. Reena S Patel | Alternate Director |
FAQ
What is the intrinsic value of Themis Medicare Ltd?
Themis Medicare Ltd's intrinsic value (as of 10 January 2026) is ₹38.11 which is 61.35% lower the current market price of ₹98.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹908 Cr. market cap, FY2025-2026 high/low of ₹272/98.0, reserves of ₹371 Cr, and liabilities of ₹582 Cr.
What is the Market Cap of Themis Medicare Ltd?
The Market Cap of Themis Medicare Ltd is 908 Cr..
What is the current Stock Price of Themis Medicare Ltd as on 10 January 2026?
The current stock price of Themis Medicare Ltd as on 10 January 2026 is ₹98.6.
What is the High / Low of Themis Medicare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Themis Medicare Ltd stocks is ₹272/98.0.
What is the Stock P/E of Themis Medicare Ltd?
The Stock P/E of Themis Medicare Ltd is .
What is the Book Value of Themis Medicare Ltd?
The Book Value of Themis Medicare Ltd is 41.3.
What is the Dividend Yield of Themis Medicare Ltd?
The Dividend Yield of Themis Medicare Ltd is 0.51 %.
What is the ROCE of Themis Medicare Ltd?
The ROCE of Themis Medicare Ltd is 10.4 %.
What is the ROE of Themis Medicare Ltd?
The ROE of Themis Medicare Ltd is 7.65 %.
What is the Face Value of Themis Medicare Ltd?
The Face Value of Themis Medicare Ltd is 1.00.